Plus Therapeutics raises $15M in private placement; exchanges $3.2M in convertible notes

PLUS THERAPEUTICS, INC.

Private placement of ~28M shares (or prefunded warrants) at $0.66/unit, each with Series A and B warrants.
Gross proceeds of ~$15M; includes exchange of $3.2M convertible notes for securities in the placement.
Company repurchases $3.4M in notes and 3M warrants for $4.25M, eliminating financing restrictions.
Believes it has regained compliance with Nasdaq minimum stockholders' equity requirement (Rule 5550(b)(1)).
Closing contingent on Nasdaq confirmation by March 31, 2025; funds held in escrow pending.

item 1.01 item 3.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-045305
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2025-03-04T23:59:59+00:00
discovered_at: 2026-05-14T18:03:02.919162+00:00
generated_at: 2026-05-25T12:42:17.684142+00:00
sec_items: ["1.01", "3.02", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-045305
json_url: https://secwatch.observer/filing/0001193125-25-045305.json
markdown_url: https://secwatch.observer/filing/0001193125-25-045305.md
text_url: https://secwatch.observer/filing/0001193125-25-045305.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/0001193125-25-045305-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/d875007d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-045305

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.